Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Tropicamide (formerly Ro-17683; Ro 1-7683; trade names Mydral; Mydriafair; Mydriaticum; Mydrum), an approved medication used to dilate the pupil and help with eye examination, is a potent anticholinergic and a muscarinic receptor isoform M4 antagonist with important biological activity. It inhibits M4-muscarinic receptor with an IC50 of 8.0 nM. It is short acting drug for mydriasis and cycloplegia when applied as eye drops.
References |
JOphthalmol.2015;2015:612728;Br J Pharmacol.1993 Dec;110(4):1413-20.
|
---|
Molecular Formula |
C17H20N2O2
|
|
---|---|---|
Molecular Weight |
284.35
|
|
CAS # |
1508-75-4
|
|
Related CAS # |
Tropicamide-d3;2673270-13-6
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
O=C(C([H])(C([H])([H])O[H])C1C([H])=C([H])C([H])=C([H])C=1[H])N(C([H])([H])C([H])([H])[H])C([H])([H])C1C([H])=C([H])N=C([H])C=1[H]
|
|
InChi Code |
InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3
|
|
Chemical Name |
N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamideInChi Key: BGDKAVGWHJFAGW-UHFFFAOYSA-N
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5168 mL | 17.5840 mL | 35.1679 mL | |
5 mM | 0.7034 mL | 3.5168 mL | 7.0336 mL | |
10 mM | 0.3517 mL | 1.7584 mL | 3.5168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04932213 | Completed | Drug: Tropicamide Ophthalmic | Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus |
Semnan University of Medical Sciences | July 7, 2021 | Phase 3 |
NCT06077682 | Recruiting | Drug: Cyclopentolate Drug: Tropicamide |
Cycloplegia Refractive Errors EsotropiaVision Disorders |
Islamic Hospital, Jordan | September 1, 2023 | Phase 4 |
NCT05442801 | Completed | Drug: Cyclopentolate Drug: Tropicamide |
Cycloplegia | Islamic Hospital, Jordan | March 1, 2022 | Phase 4 |
NCT01844648 | Completed | Drug: NH004 tropicamide Drug: NH004 Placebo |
Sialorrhea (Excessive Drooling) | NeuroHealing Pharmaceuticals Inc. | April 2013 | Phase 2 |
NCT03097198 | Unknown † | Other: Plum-blossom Needle Drug: Tropicamide Eye Drops |
Myopia | Wenzhou Medical University | December 2016 | Not Applicable |